Roivant Sciences Ltd.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | $8.3M | $29.1M | $32.7M | $31.5M | $55.3M | $23.8M |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | $681.8M | $550.4M | $439.9M | $454.1M | $483.0M | $236.6M |
| SG&A Expense | $610.5M | $591.4M | $687.4M | $600.5M | $775.0M | $259.9M |
| Operating Income | $-515.1M | $-1.00B | $4.50B | $-906.8M | $-1.35B | $-1.07B |
| Operating Margin | -6,235.7% | -3,453.3% | 13,746.9% | -2,875.9% | -2,444.8% | -4,500.5% |
| Interest Expense | — | — | $34.8M | $28.0M | $7.0M | $2.8M |
| Pretax Income | $-264.6M | $-681.6M | $4.57B | $-885.0M | $-923.7M | $-898.5M |
| Income Tax Expense | $133.3M | $48.2M | $21.5M | $4.1M | $369.0K | $1.7M |
| Net Income | $-299.8M | $-172.0M | $4.35B | $-1.01B | $-845.3M | $-809.2M |
| Net Margin | -3,629.2% | -592.0% | 13,294.2% | -3,200.2% | -1,528.9% | -3,400.9% |
| EPS (Basic) | $-0.43 | $-0.24 | $5.55 | $-1.42 | $-1.26 | $-1.28 |
| EPS (Diluted) | $-0.54 | $-0.24 | $5.23 | $-1.42 | $-1.26 | $-1.28 |
| Shares Outstanding (Basic) | 693.9M | 725.4M | 783.2M | 712.8M | 669.8M | 651.6M |
| Shares Outstanding (Diluted) | 693.9M | 725.4M | 831.0M | 712.8M | 669.8M | 651.6M |
| Dividends Per Share | — | — | — | — | — | — |